Quarterly report pursuant to Section 13 or 15(d)

Royalty and Commercial Payment Purchase Agreements - Viracta (Details)

v3.24.2.u1
Royalty and Commercial Payment Purchase Agreements - Viracta (Details)
$ in Thousands
 3 Months Ended 6 Months Ended
May 30, 2024
USD ($)
Oct. 30, 2023
USD ($)
Mar. 22, 2021
USD ($)
item
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Jun. 30, 2024
USD ($)
Jun. 30, 2023
USD ($)
Dec. 31, 2023
USD ($)
Agreements                
Payments of consideration under RPAs, AAAs and CPPAs           $ 37,000 $ 14,650  
Short-term royalty and commercial payment receivables       $ 14,257   14,257   $ 14,215
Long-term royalty and commercial payment receivables       69,731   69,731   57,952
Trade and other receivables, net       526   526   1,004
Viracta                
Agreements                
Reduction in long-term royalty receivable balance due to receipt of payment           8,500    
Viracta | Royalty Purchase Agreement                
Agreements                
Number of drug candidates | item     2          
Payments of consideration under RPAs, AAAs and CPPAs     $ 13,500          
Maximum amount of potential milestones, potential royalties on sales and other payments receivable     54,000          
Amount of maximum consideration retained     5,000          
Maximum amount of potential regulatory and commercial milestones receivable     57,000          
Acquisition of royalty and commercial payment receivables, Long-Term     $ 13,500          
Amount of milestone payments earned under agreement   $ 5,000       9,000    
Reduction in long-term royalty receivable balance due to receipt of payment   $ 5,000       8,500    
Income from purchased receivables       900 $ 0 900 $ 0  
Sale of priority review voucher to undisclosed buyer $ 108,000              
Long-term royalty and commercial payment receivables       0   0    
Amount of allowance for credit losses               0
Trade and other receivables, net       $ 400   400   $ 0
Viracta | Royalty Purchase Agreement | OJEMDA                
Agreements                
Income from purchased receivables           500    
Viracta | Royalty Purchase Agreement | Priority review voucher.                
Agreements                
Income from purchased receivables           $ 8,100